Reliability of antimalarial sensitivity tests depends on drug mechanisms of action.
about
Tetracyclines in malariaChloroquine clinical failures in P. falciparum malaria are associated with mutant Pfmdr-1, not Pfcrt in MadagascarP. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-actionAn image analysis algorithm for malaria parasite stage classification and viability quantificationA novel flow cytometric hemozoin detection assay for real-time sensitivity testing of Plasmodium falciparumA chemical proteomics approach for the search of pharmacological targets of the antimalarial clinical candidate albitiazolium in Plasmodium falciparum using photocrosslinking and click chemistryHigh-throughput analysis of antimalarial susceptibility data by the WorldWide Antimalarial Resistance Network (WWARN) in vitro analysis and reporting tool.Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis.A high-throughput screen targeting malaria transmission stages opens new avenues for drug developmentMultinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine.Assessing anti-malarial drug effects ex vivo using the haemozoin detection assay.Identifying rapidly parasiticidal anti-malarial drugs using a simple and reliable in vitro parasite viability fast assayMolecular Markers and In Vitro Susceptibility to Doxycycline in Plasmodium falciparum Isolates from Thailand.The Redox Cycler Plasmodione Is a Fast-Acting Antimalarial Lead Compound with Pronounced Activity against Sexual and Early Asexual Blood-Stage Parasites.Comparison between Flow Cytometry, Microscopy, and Lactate Dehydrogenase-Based Enzyme-Linked Immunosorbent Assay for Plasmodium falciparum Drug Susceptibility Testing under Field ConditionsInvestigating antimalarial drug interactions of emetine dihydrochloride hydrate using CalcuSyn-based interactivity calculations.Optimizing the HRP-2 in vitro malaria drug susceptibility assay using a reference clone to improve comparisons of Plasmodium falciparum field isolates.Mechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria.Plasmodium falciparum In Vitro Resistance to Monodesethylamodiaquine, Dakar, Senegal, 2014.Direct comparison of the histidine-rich protein-2 enzyme-linked immunosorbent assay (HRP-2 ELISA) and malaria SYBR green I fluorescence (MSF) drug sensitivity tests in Plasmodium falciparum reference clones and fresh ex vivo field isolates from CambCRIMALDDI: platform technologies and novel anti-malarial drug targets.Confirmation of Plasmodium falciparum in vitro resistance to monodesethylamodiaquine and chloroquine in Dakar, Senegal, in 2015.Susceptibility Testing of Medically Important Parasites.A novel live-dead staining methodology to study malaria parasite viability.Absolute bioavailability of cis-mirincamycin and trans-mirincamycin in healthy rhesus monkeys and ex vivo antimalarial activity against Plasmodium falciparum.High Accumulation and In Vivo Recycling of the New Antimalarial Albitiazolium Lead to Rapid Parasite Death.Simple flow cytometric detection of haemozoin containing leukocytes and erythrocytes for research on diagnosis, immunology and drug sensitivity testing.New insight into the mechanism of accumulation and intraerythrocytic compartmentation of albitiazolium, a new type of antimalarial.Antimalarial drug sensitivity profile of western Kenya Plasmodium falciparum field isolates determined by a SYBR Green I in vitro assay and molecular analysis.Optimal dose finding for novel antimalarial combination therapy.Development in Assay Methods for in Vitro Antimalarial Drug Efficacy Testing: A Systematic Review.High-Content Screening of MMV Pathogen Box for Plasmodium falciparum Digestive Vacuole Disrupting Molecules Reveals Valuable Starting Points for Drug Discovery.
P2860
Q26778176-C1F82749-BF1B-458B-811A-AEBE26A2ACB1Q28475757-21F591E5-CE10-49A4-B6CE-315C88897827Q28481199-7D8A96D3-1FD4-4DEC-9281-A9FD7C4D9EC7Q28486636-8A09D5DD-2375-4629-BC09-283AC70233C1Q28486811-4CC5AC4D-9357-487D-8464-A7D5A3765665Q28542452-D5B431F3-4367-4B02-99BD-94DD95194FE8Q30619647-B7638323-FFF8-4F0B-A917-AC5C204518AEQ34707761-3FE7978B-42CE-4E83-9EB1-1BADD5D0AAA0Q34833899-2F26B8BA-39A4-4AF3-A5F3-F537D9E987E1Q35068138-45F69429-9551-471E-A9B2-23CD67645839Q35368698-65A6FE7F-728D-41A1-9365-4B40C517192BQ35834164-9E977026-7B54-4718-B119-CD87DC923178Q35860167-23C2F34C-B9E2-4B4D-8141-70F511CF370FQ36051237-B44D78F9-44B9-4C5E-B7A6-FF643D67F0F8Q36066881-070DD25E-FA0E-4454-8C3A-21F9F880F1CCQ36296803-56AC3CAD-6AED-4C16-A396-DCEA67EF0569Q36372815-25754850-D99F-488F-B76D-CE01F905B87EQ36505504-7EBD0F87-A3E5-4D79-8298-8A58322B3187Q36884930-39A4EB14-9C66-4538-939C-657D4E8C088EQ37028482-27B7F73F-6603-4E6E-8C29-ED4BFECF9536Q37308061-990582E4-6408-4BC1-8C96-5BF468294090Q37708245-498813A1-8CEB-4750-BA9A-53D36653480DQ39020376-2852B1D0-563C-453F-99A3-7BB1CC7C381AQ39341007-40F6B9E0-75B3-4C73-8371-75AA240BF996Q39660163-4F803CE8-DA2B-41A8-8128-B3EBE6AA18E5Q40175227-2D7499DE-5B80-4AAF-ADE3-C35481FFB96EQ41774489-1DBF38D1-F847-4290-9C10-382A6CD2121AQ41920840-304FB4CC-7666-4E02-B2F2-368D132A373CQ41932353-91926EF4-EA90-445D-B8D9-3F57FB88B7CBQ42210267-D54364F1-A7AE-466F-8F25-DE9E7A024BA9Q45770576-D332F12F-BDD1-4021-985D-4A1710D1996EQ47193275-275B2625-EB14-47DB-B2CB-52FA17E460A2
P2860
Reliability of antimalarial sensitivity tests depends on drug mechanisms of action.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Reliability of antimalarial sensitivity tests depends on drug mechanisms of action.
@en
type
label
Reliability of antimalarial sensitivity tests depends on drug mechanisms of action.
@en
prefLabel
Reliability of antimalarial sensitivity tests depends on drug mechanisms of action.
@en
P2093
P2860
P356
P1476
Reliability of antimalarial sensitivity tests depends on drug mechanisms of action
@en
P2093
Christophe Tran Van Ba
Henri Vial
Laurent Fraisse
Marjorie Maynadier
Suzanne Peyrottes
P2860
P304
P356
10.1128/JCM.02250-09
P407
P577
2010-03-10T00:00:00Z